ÁREA: CÁNCER

Grupo: Hematología Experimental
(Inmunoterapia celular)

Inmunoterapia con células CAR-T: limitaciones y estrategias para mejorar la persistencia y eficacia del tratamiento

Beatriz Martín-Antonio
beatriz.antonio@quironsalud.es

IV REUNIÓN ANUAL DEL ÁREA DE CÁNCER DEL IIS-FJD
23 de marzo del 2022

UAM Universidad Autónoma de Madrid

Hospital Universitario
Fundación Jiménez Díaz
Grupo quironsalud

IIS
FJD
INSTITUTO DE INVESTIGACIÓN SANITARIA
FUNDACIÓN JIMÉNEZ DÍAZ

CAR-T cell immunotherapy

2nd generation CAR

1st patient successfully treated (2011)

Pediatric R/R ALL (Kymriah)

	No. of Patients	No. of Events	Median Survival *mo*	Rate at 6 Mo % (95% CI)
Overall Survival	75	19	19.1	90 (81–95)
Event-free Survival	75	27	not reached	73 (60–82)

1st CARs approved in EU (2018): 1) Yescarta (Gilead/Kite Pharma): CART19 (CD28)   2) Kymriah (Novartis): CART19 (4-1BB)

R/R some types of NHL, follicular lymphoma.
DFS: 51%

R/R B-ALL up to 25 years old, adults R/R DLBCL.
DFS: 62% ALL, 64% DLBCL

Currently: 6 FDA-approved CAR-T cell therapies (CD19 and BCMA) in R/R patients:

Tecartus (MCL, ALL)   Abecma (MM)

Breyanzi (NHL)   Carvykti (MM)

None in solid tumors

Failure to CAR-T treatment

Failure of production of autologous CAR-T cells
(Universal allogeneic CARs)

CAR-T cell infusion to the patient

Lack of initial efficacy: early disappearance of CAR-T
(CAR construct: AICD, immunogenicity)

Objective responses

Relapses

Permanent responses

Loss of expression of the target Ag
(related to the Ag)

Lack of persistence/efficacy of CAR-T cells

Kymriah: CART19 (4-1BB) Pediatric/young ALL

OR= 81%; CR=60%

At relapse:
68% pat have lost CD19

Maude SL, et al. NEJM, 2018

CART-BCMA in R/R MM
CILTA-CEL (JNJ4528) *vs* IDE-CEL: FDA/EMA approved
OR=98, CR=80%   OR=73%, CR=33%

At relapse:
Loss of BCMA suspected in 4% pat.

Relapses despite initial CR

HR [95%CI]; p-value
Cilta-cel Observed vs Ide-cel: 0.26 [0.17,0.40], <.0001
Cilta-cel Adjusted vs Ide-cel: 0.36 [0.22,0.59], <.0001

Kymriah in R/R DLBCL

OR= 52%; CR=40%


Patients with complete response

All patients

Schuster SJ, et al. NEJM, 2019

Compared to SOC, 2nd line

No superiority (Kymriah):
Bishop, M. et al. NEJM. 2022

Superiority (Yescarta)
Locke, F.L. et al. NEJM. 2022

CAR-T cell immunotherapy: strategies to improve

Failure to CAR-T treatment

Failure of production of autologous CAR-T cells
(Universal allogeneic CARs)

CAR-T cell infusion to the patient

Lack of initial efficacy: early disappearance of CAR-T
(CAR construct: AICD, immunogenicity)

Objective responses

Relapses

Permanent responses

Loss of expression of the target Ag
(related to the Ag)

Lack of persistence/efficacy of CAR-T cells

CAR construct
(efficacy)

Immunosenescence
(persistence)

TME
(resistance mechanisms)

Main targets in our group:

Mature B-cell malignancies (NHL and MM)
Solid tumors (collaborations)

CAR construct: increased efficacy

Source of monoclonal Ab
Hinge/spacer
Transmembrane
Costimulatory domain
Duals, bicistronics, cocktail of CARs, other immune cells

Phenotype of T cell, selection of cell populations
Suicide genes
Source of cell: Universal CARs
Multiple CARs from one construct: SUPRA CARs
Affinity Tunning CARs

Our previous results: CART cells against BCMA in MM (ARI2h cells)

Plasma Cell Disorders

Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma

Lorena Perez-Amill,[1] Guillermo Suñe,[1] Asier Antoñana-Vildosola,[1] Maria Castella,[1] Amer Najjar,[2] Jaume Bonet,[3] Narcis Fernández-Fuentes,[4] Susana Inogés,[5] Ascensión López,[5] Clara Bueno,[6] Manel Juan,[7] Alvaro Urbano-Ispizua[1,8,9] and Beatriz Martín-Antonio[1,8]

[1]Department of Hematology, Hospital Clinic, IDIBAPS, Barcelona, Spain; [2]Department of Pediatrics - Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; [3]Laboratory of Protein Design and Immunoengineering, École Polytechnique

Ferrata Storti F

Open access

Journal for ImmunoTherapy of Cancer

Original research

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness

Mireia Bachiller,[1] Lorena Perez-Amill,[1] Anthony Matthew Battram [1], Sebastian Ciro Carné,[1] Amer Najjar,[2] Els Verhoeyen,[3,4] Manel Juan [5,6], Alvaro Urbano-Ispizua,[7,8] Beatriz Martin-Antonio [9]

# Pre-clinical development of ARI2m and ARI2h cells for the treatment of MM:

ARI2h and ARI2m in a model of high tumor burden: ARI2h shows superiority to ARI2m:

CB-NK enhances *in vitro* ARI2h and UT T cell efficacy, with no increased cytokine production

CB-NK increases ARI2h fitness

Immunosenescence: deterioration of the immune system associated to aging

## Multiple mieloma: elderly population

Immmunosenescence: Progressive decline in the immune function associated to aging (Multiple myeloma)

T cell differentiation and immunosenescence

Memory

Proliferative potential, length life

Naïve T cell — T Stem cell memory — T Central Memory — T Effector Memory — T Effector

Effector

Differentiation

Factors:
Diseases, chronic inflammation, viral infections, cancer
Thymic involution: decreased pool of naïve T cells
In Bone marrow: replacement of cells by adipocytes

T_{CM}: permanent responses (>10 yrs)

EM and Effector: short life

% Naïve T cells in Healthy children:

~80%: 0-2 years
~70%: 2-6 years
~60%: 6-12 years
~50%: 18 years

Clinical production of CART cells

Castella M, et. al.
Front. Immunol,2020

Enhanced in MM
CD8: exhausted and senescent

Claudia Zelle-Rieser, et al.
J Hematol Oncol. 2016

## Chemotherapy induced immunosenescence in T cells in cancer patients

SR ALL   HR ALL   NHL

Rhabdomyosarcoma   Ewing sarcoma

Cycles of chemotherapy

Terminal effector
Effector memory
Central memory
Stem memory
Naïve

All pat. up to 21 years

Rajat K Das et al.
Cancer Discov. 2019;9(4)

Tumor microenvironment: resistance mechanisms

1) SILAC proteomics

CAR proteins: enhancement of the efficacy

Tumor proteins: avoiding tumor resistance

- Tumor proteins
- CAR proteins

4th generation CAR
(tumor inhibition)

CAR persistence

2) TME characterization

Tumor Tissue

Immunofluorescence

Labeled Ab

BM
characterization

3D
in vitro models

SILAC proteomics
CAR persistence